Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913483 · ClinicalTrials.gov registry record · Phase 3
ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial
A Phase 3 study, sponsored by The Medicines Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 732
- Enrollment target
NCT01913483 is a Phase 3 study that was terminated before completion, run by The Medicines Company. The registered enrollment target is 732 participants.
The verdict
NCT01913483, a Phase 3 study, was terminated before completion, sponsored by The Medicines Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 732 participants
- Enrollment target
Study Summary
The primary objective of the study is to test whether anticoagulation with bivalirudin results in fewer major bleeding complications compared with unfractionated heparin (UFH) in participants undergoing peripheral endovascular interventions (PEI). The secondary objective is to test whether there were potential benefits from bivalirudin therapy on other clinically important events such as death, myocardial infarction (MI), stroke and/or transient ischemic attack (TIA), amputation, unplanned repeat revascularization (URV), and minor bleeding, as well as potential economic benefits that may result from improved clinical outcomes.
Interventions
- DRUG Bivalirudin
- DRUG Unfractionated Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2013-09-24 |
| Est. Completion | 2016-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01913483
The ClinicalTrials.gov registry entry for NCT01913483 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bivalirudin is the first listed.
NCT01913483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01913483 about?
NCT01913483 is a clinical study titled "ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial". The primary objective of the study is to test whether anticoagulation with bivalirudin results in fewer major bleeding complications compared with unfractionated heparin (UFH) in participants undergoing peripheral endovascular interventions (PEI). The secondary objective is to test whether there wer...
What is the current status of trial NCT01913483?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 732 participants. The study started on 2013-09-24. Estimated completion is 2016-03-16.
What interventions are being tested in trial NCT01913483?
The interventions under investigation include: Bivalirudin (DRUG), Unfractionated Heparin (DRUG).
Who is sponsoring clinical trial NCT01913483?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.